Related Experiment Videos
Update on malignant ovarian germ cell tumors
1Department of Gynecology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Cancer
|February 15, 1993
Summary
Malignant ovarian germ cell tumor therapy has seen remarkable progress, with chemotherapy regimens like bleomycin, etoposide, and cisplatin achieving over 95% disease-free survival. Research continues to refine treatments and preserve reproductive potential in young patients.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background:
- Malignant ovarian germ cell tumors (OGCTs) have a complex treatment history.
- Significant advancements have been made in understanding and managing these rare cancers.
Purpose of the Study:
- To review the evolution of OGCT therapy, highlighting recent developments.
- To emphasize standardized nomenclature, treatment protocols, and survival outcomes.
Main Methods:
- Review of major advances in OGCT treatment over the past two decades.
- Emphasis on standardized histologic criteria and chemotherapeutic regimens.
- Analysis of treatment outcomes, including survival rates and late effects.
Main Results:
- Standardized nomenclature and histologic criteria for OGCT subtypes.
- Bleomycin, etoposide, and cisplatin (BEP) regimen as the current gold standard, yielding >95% disease-free survival.
- Chemotherapy is now preferred over radiation for metastatic dysgerminoma.
- Alternative regimens (vinblastine, ifosfamide, cisplatin) for platinum-sensitive resistant tumors are under investigation.
- Studies indicate preservation of reproductive potential in most young patients.
Conclusions:
- Therapy for malignant ovarian germ cell tumors represents a major success in oncology.
- Current chemotherapy regimens offer excellent survival rates.
- Ongoing research focuses on optimizing treatment for resistant cases and minimizing long-term side effects.